Use of hydroxyurea in French-speaking Sub-Saharan Africa

IF 2.4 3区医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2025-02-05 DOI:10.1007/s00277-024-06180-2

Jean-Benoît Arlet, Françoise Bernaudin, Indou Deme-Ly, Binta Coulibaly, Anne Corbasson, Ibrahima Diagne, Dapa Diallo, Saliou Diop, Charlotte Eposse, Frédéric Galacteros, Olivier Hermine, Eléonore Kafando, Agnès Lainé, Mariane de Montalembert, Constant Vodouhé, Ahoefa Vovor, Brigitte Ranque, Léon Tshilolo

{"title":"Use of hydroxyurea in French-speaking Sub-Saharan Africa","authors":"Jean-Benoît Arlet, Françoise Bernaudin, Indou Deme-Ly, Binta Coulibaly, Anne Corbasson, Ibrahima Diagne, Dapa Diallo, Saliou Diop, Charlotte Eposse, Frédéric Galacteros, Olivier Hermine, Eléonore Kafando, Agnès Lainé, Mariane de Montalembert, Constant Vodouhé, Ahoefa Vovor, Brigitte Ranque, Léon Tshilolo","doi":"10.1007/s00277-024-06180-2","DOIUrl":null,"url":null,"abstract":"<div><p>The hydroxyurea is a save, affordable and essential medicine for sickle cell disease (SCD), reducing painful crises and mortality. To foster the prescription of hydroxyurea for patients with SCD in sub-Saharan African countries, the scientific advisory board of Drep.Afrique, a non-governmental organization dedicated to SCD in Africa, has developed a therapeutic guideline well suited to conditions on the ground. These guidelines answer three essential questions: which patients should be prioritized for treatment with hydroxyurea, which dose should be used, and what follow-up should be implemented in those low-resources countries?</p><p> The guidelines are given as in a concise document for easy use by practitioners on the ground, available in English and in French.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 2","pages":"937 - 941"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-024-06180-2.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-024-06180-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The hydroxyurea is a save, affordable and essential medicine for sickle cell disease (SCD), reducing painful crises and mortality. To foster the prescription of hydroxyurea for patients with SCD in sub-Saharan African countries, the scientific advisory board of Drep.Afrique, a non-governmental organization dedicated to SCD in Africa, has developed a therapeutic guideline well suited to conditions on the ground. These guidelines answer three essential questions: which patients should be prioritized for treatment with hydroxyurea, which dose should be used, and what follow-up should be implemented in those low-resources countries?

The guidelines are given as in a concise document for easy use by practitioners on the ground, available in English and in French.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

羟基脲在撒哈拉以南非洲法语区的使用。

羟基脲是治疗镰状细胞病（SCD）的一种节省、负担得起的基本药物，可以减少痛苦的危机和死亡率。为了促进撒哈拉以南非洲国家SCD患者的羟基脲处方，Drep的科学顾问委员会。非洲是一个致力于非洲SCD的非政府组织，它制定了一项非常适合当地情况的治疗指南。这些指南回答了三个基本问题：哪些患者应该优先接受羟基脲治疗，应该使用多大剂量，以及在资源匮乏的国家应该实施什么样的随访？这些准则以简明的文件形式提供，方便实地从业人员使用，有英文和法文两种版本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.